Download PDF
Z Gastroenterol 2015; 53(04): 320-334
DOI: 10.1055/s-0034-1399322
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Aktuelle Empfehlung zur Therapie der chronischen Hepatitis C[1]

S3 guideline hepatitis C addendum
C. Sarrazin
1   Med. Klinik 1, Universitätsklinikum Frankfurt, Frankfurt am Main, Germany
,
T. Berg
2   Klinik und Poliklinik für, Universitätsklinikum Leipzig, Leipzig, Germany
,
P. Buggisch
3   Leberzentrum Hamburg, Institut für Interdisziplinäre Medizin, IFI, Hamburg, Germany
,
M. M. Dollinger
4   Innere Medizin I, Universitätsklinik Ulm, Germany
,
H. Hinrichsen
5   Gastroenterologisch-Hepatologisches Zentrum Kiel, Germany
,
H. Hofer
6   Division of Gastroenterology and Hepatology Medical University of Vienna, Wien, Austria
,
D. Hüppe
7   Gastroenterologische Gemeinschaftspraxis Herne, Germany
,
M. P. Manns
8   Medizinische Hochschule Hannover, Germany
,
S. Mauss
9   Center for HIV and Hepatogastroenterology, Düsseldorf, Germany
,
J. Petersen
3   Leberzentrum Hamburg, Institut für Interdisziplinäre Medizin, IFI, Hamburg, Germany
,
K.-G. Simon
10   MVZ für Gastroenterologie und Hepatologie, Leverkusen, Germany
,
I. van Thiel
11   Deutsche Leberhilfe e.V., Köln, Germany
,
H. Wedemeyer
8   Medizinische Hochschule Hannover, Germany
,
S. Zeuzem
1   Med. Klinik 1, Universitätsklinikum Frankfurt, Frankfurt am Main, Germany
› Author Affiliations
Further Information

Publication History

18 February 2015

08 March 2015

Publication Date:
13 April 2015 (online)

Also available at
    Permissions and Reprints

Präambel

Durch die Zulassung der direkt antiviral wirksamen Medikamente gegen verschiedene Proteine des Hepatitis-C-Virus (HCV) wurde die Möglichkeit einer hocheffektiven, nebenwirkungsarmen interferonfreien Kombinationstherapie mit relativ kurzer Therapiedauer für praktisch alle Patienten mit einer chronischen Hepatitis-C-Virus-Infektion (HCV) eröffnet.

Vor diesem Hintergrund kann eine interferonbasierte Therapie nicht mehr als Standardtherapie empfohlen werden.

Die folgenden Empfehlungen gelten für erwachsene Patienten mit chronischer Hepatitis C.

1 Addendum zur Hepatitis-C-Leitlinie im Auftrag der folgenden Fachgesellschaften (2/15): Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)/Berufsverband niedergelassener Gastroenterologen (bng), Kompetenznetz Hepatitis /Deutsche Leberstiftung, Deutsche Gesellschaft für Pathologie (DGP)/Berufsverband Deutscher Pathologen, Gesellschaft für Virologie (GfV), Gesellschaft für Pädiatrische Gastroenterologie und Ernährung (GPGE), Schweizerische Gesellschaft für Gastroenterologie (SGG), Österreichische Gesellschaft für Gastroenterologie und Hepatologie (ÖGGH), Deutsche Transplantationsgesellschaft (DTG), Deutsche Leberhilfe e. V.


 

  • Literatur

  • 1 Afdhal N, Zeuzem S, Kwo P et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-1898
    CrossrefPubMedGoogle Scholar
  • 2 Bourliere M, Sulkowski MS, Omata M et al. An Integrated Safety and Efficacy Analysis of > 500 Patients with Compensated Cirrhosis Treated with Ledipasvir/Sofosbuvir with or without Ribavirin. Hepatology 2014; 60: 239A
    PubMedGoogle Scholar
  • 3 Kowdley KV, Gordon SC, Reddy KR et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-1888
    CrossrefPubMedGoogle Scholar
  • 4 Afdhal N, Reddy KR, Nelson DR et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-1493
    CrossrefPubMedGoogle Scholar
  • 5 Ferenci P, Bernstein D, Lalezari J et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370: 1983-1992
    CrossrefPubMedGoogle Scholar
  • 6 Feld JJ, Kowdley KV, Coakley E et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1594-16031
    CrossrefPubMedGoogle Scholar
  • 7 Poordad F, Hezode C, Trinh R et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370: 1973-1982
    CrossrefPubMedGoogle Scholar
  • 8 Everson GT, Dusheiko G, Coakley E et al. Integrated Efficacy Analysis of Four Phase 3 Studies in HCV Genotype 1a-Infected Patients Treated with ABT450/r/Ombitasvir and Dasabuvir With or Without Ribavirin. Hepatology 2014; 60: 239a-240a
    PubMedGoogle Scholar
  • 9 Zeuzem S, Jacobson IM, Baykal T et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1604-1614
    CrossrefPubMedGoogle Scholar
  • 10 Andreone P, Colombo MG, Enejosa JV et al. ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection. Gastroenterology 2014; 147: 359-365
    CrossrefPubMedGoogle Scholar
  • 11 Lawitz E, Sulkowski MS, Ghalib R et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756-1765
    CrossrefPubMedGoogle Scholar
  • 12 Dieterich D, Bacon BR, Flamm SL et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. Hepatology 2014; 60: 220a-220a
    PubMedGoogle Scholar
  • 13 Jensen DM, O'Leary JG, Pockros PJ et al. Safety and Efficacy of Sofosbuvir-Containing Regimens for Hepatitis C. Real-World Experience in a Diverse, Longitudinal Observational Cohort. Hepatology 2014; 60: 219a-220a
    PubMedGoogle Scholar
  • 14 Sulkowski MS, Gardiner DF, Rodriguez-Torres M et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J.Med 2014; 370: 211-221
    CrossrefPubMedGoogle Scholar
  • 15 Gane EJ, Stedman CA, Hyland RH et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44
    CrossrefPubMedGoogle Scholar
  • 16 Osinusi A, Meissner EG, Lee YJ et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013; 310: 804-811
    CrossrefPubMedGoogle Scholar
  • 17 Lalezari JP, Nelson DR, Hyland RH et al. Once Daily Sofosbuvir Plus Ribavirin for 12 and 24 Weeks in Treatment-Naive Patients with Hcv Infection: the Quantum Study. Journal of Hepatology 2013; 58: S346-S346
    PubMedGoogle Scholar
  • 18 Zeuzem S, Hezode C, Bronowicki JP et al. Daclatasvir in combination with simeprevir with or without ribavirin for hepatitis C virus genotype 1 infection. 21st Conferences on Retroviruses and Opportunistic Infections; 2014
    PubMedGoogle Scholar
  • 19 Lawitz E, Mangia A, Wyles D et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887
    CrossrefPubMedGoogle Scholar
  • 20 Kowdley KV, Lawitz E, Crespo I et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381: 2100-2107
    CrossrefPubMedGoogle Scholar
  • 21 Pol S, Sulkowski M, Hassanein T et al. Successful retreatment with sofosbuvir of HCV genotype-1 infected patients who failed prior therapy with peginterferon and ribavirin plus 1 or 2 additional direct-acting antiviral agents. Journal of Hepatology 2014; 60: S23-S23
    PubMedGoogle Scholar
  • 22 Lawitz E, Poordad F, Brainard D et al. Sofosbuvir in combination with PEG-IFN and ribavirin for 12 weeks provides high SVR rates in HCV infected genotype 2 or 3 treatment-experienced patients with and without compensated cirrhosis: results from the Lonestar-2 study. Hepatology 2013; 58: LB-4
    PubMedGoogle Scholar
  • 23 Forns X, Lawitz E, Zeuzem S et al. Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial. Gastroenterology 2014; 146: 1669-1679
    CrossrefPubMedGoogle Scholar
  • 24 Manns M, Marcellin P, Poordad F et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014; 384: 414-426
    CrossrefPubMedGoogle Scholar
  • 25 Jacobson IM, Dore GJ, Foster GR et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384: 403-413
    CrossrefPubMedGoogle Scholar
  • 26 Vermehren J, Aghemo A, Falconer K et al. Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. J Hepatol 2014; 60: 913-919
    CrossrefPubMedGoogle Scholar
  • 27 Reddy K, Zeuzem S, zoulim F et al. A Phase III randomised, double-blind study to evaluate the efficacy, safety and tolerability of simeprevir vs telaprevir in combination with pegylated interferon and ribavirin in chronic hepatitis C virus genotype 1 treatment-experienced patients: the ATTAIN study. Hepatol Int 2014; 8: S397
    PubMedGoogle Scholar
  • 28 Hezode C, Hirschfield GM, Ghesquiere W et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut 2014; epub ahead of print
    PubMedGoogle Scholar
  • 29 Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. New England Journal of Medicine 2011; 364: 2405-2416
    CrossrefPubMedGoogle Scholar
  • 30 Poordad F, McCone Jr J, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206
    CrossrefPubMedGoogle Scholar
  • 31 Sarrazin C, Schwendy S, Möller B et al. Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks. Gastroenterology 2011; 141: 1656-1664
    CrossrefPubMedGoogle Scholar
  • 32 Sarrazin C, Berg T, Ross RS et al. Update der S3-Leitlinie Prophylaxe, Diagnose und Therapie der Hepatitis C Virus (HCV) Infektion. Z Gastroenterol 2010; 48: 289-351
    Google Scholar
  • 33 Jacobson IM, Gordon SC, Kowdley KV et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-1877
    CrossrefPubMedGoogle Scholar
  • 34 Lawitz E, Lalezari JP, Hassanein T et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13: 401-408
    CrossrefPubMedGoogle Scholar
  • 35 Zeuzem S, Dusheiko GM, Salupere R et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001
    CrossrefPubMedGoogle Scholar
  • 36 Nelson DR, Cooper JN, Lalezari JP et al. All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase 3 Study. Hepatology 2015; epub ahead of print
    PubMedGoogle Scholar
  • 37 Link JO, Taylor JG, Xu LH et al. Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection. Journal of Medicinal Chemistry 2014; 57: 2033-2046
    CrossrefPubMedGoogle Scholar
  • 38 Cheng G, Peng B, Corsa A et al. Antiviral Activity and Resistance Profile of the Novel Hcv Ns5a Inhibitor Gs-5885. Journal of Hepatology 2012; 56: S464-S464
    PubMedGoogle Scholar
  • 39 Gane EJ, Hyland RH, An D et al. High Efficacy of LDV/SOF Regimens for 12 Weeks for Patients with HCV Genotype 3 or 6 Infection. Hepatology 2014; 60: 1274a-1275a
    PubMedGoogle Scholar
  • 40 Kapoor R, Kohli A, Sidharthan S et al. All Oral Treatment for Genotype 4 Chronic Hepatitis C Infection with Sofosbuvir and Ledipasvir: Interim Results from the NIAID SYNERGY Trial. Hepatology 2014; 60: 321a-321a
    PubMedGoogle Scholar
  • 41 Pol S, Reddy KR, Baykal T et al. Interferon-Free Regimens of Ombitasvir and ABT-450/r With or Without Ribavirin in Patients With HCV Genotype 4 Infection: PEARL-I Study Results. Hepatology 2014; 60: 1129a-1130a
    PubMedGoogle Scholar
  • 42 Moreno C, Hezode C, Marcellin P et al. Once-daily simeprevir (TMC435) with peginterferon/ribavirin in treatment-naive or treatment-experienced chronic HCV genotype 4-infected patients: final results of a phase III trial. Journal of Hepatology 2014; 60: S535-S535
    PubMedGoogle Scholar
  • 43 Lenz O, Vijgen L, Berke JM et al. Virologic response and characterisation of HCV genotype 2- 6 in patients receiving TMC435 monotherapy (study TMC435-C202). J Hepatol 2013; 58: 445-451
    CrossrefPubMedGoogle Scholar
  • 44 Ruane PJ, Ain D, Meshrekey R et al. Sofosbuvir plus ribavirin, an interferon-free regimen, in the treatment of treatment-naive and treatment-experienced patients with chronic genotype 4 HCV infection. Journal of Hepatology 2014; 60: S503-S504
    PubMedGoogle Scholar
  • 45 Sulkowski MS, Rodriguez-Torres M, Lalezari J et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (Photon-1). Hepatology 2013; 58: 313A
    CrossrefPubMedGoogle Scholar
  • 46 Townsend KS, Osinusi A, Nelson AK et al. High Efficacy of Sofosbuvir/Ledipasvir for the Treatment of HCV Genotype 1 in Patients Coinfected With HIV on or off Antiretroviral therapy: Results from The NIAID ERADICATE Trial. Hepatology 2014; 60: 240a-241a
    PubMedGoogle Scholar
  • 47 Wyles DL, Sulkowski MS, Eron JJ et al. TURQUOISE-I: 94% SVR12 in HCV/HIV-1 Coinfected Patients Treated with ABT-450/r/Ombitasvir, Dasabuvir and Ribavirin. Hepatology 2014; 60: 1136a-1137a
    CrossrefPubMedGoogle Scholar
  • 48 Rodriguez-Torres M, Rodriguez-Orengo J, Gaggar A et al. Sofosbuvir and peginterferon alfa-2a/ribavirin for treatment-naive genotype 1-4 HCV-infected patients who are coinfected with HIV. Infectious Disease Week; 2014 2014A
    PubMedGoogle Scholar
  • 49 Reddy KR, Everson GT, Flamm SL et al. Ledipasvir/Sofosbuvir with Ribavirin for the Treatment of HCV in Patients with Post Transplant Recurrence: Preliminary Results of a Prospective, Multicenter Study. Hepatology 2014; 60: 200a-201a
    CrossrefPubMedGoogle Scholar
  • 50 Flamm SL, Everson GT, Charlton M et al. Ledipasvir/Sofosbuvir with Ribavirin for the Treatment of HCV in Patients with Decompensated Cirrhosis: Preliminary Results of a Prospective, Multicenter Study. Hepatology 2014; 60: 320a-321a
    PubMedGoogle Scholar
  • 51 Mantry PS, Kwo PY, Coakley E et al. High Sustained Virologic Response Rates in Liver Transplant Recipients With Recurrent HCV Genotype 1 Infection Receiving ABT-450/r/Ombitasvir plus Dasabuvir Plus Ribavirin. Hepatology 2014; 60: 298a-299a
    PubMedGoogle Scholar
  • 52 Curry MP, Forns X, Chung RT et al. Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection After Liver Transplantation: An Open-Label Study. Gastroenterology 2015; 148: 100-U519
    CrossrefPubMedGoogle Scholar
  • 53 Lawitz E, Ghalib R, Rodriguez-Torres M et al. Simeprevir plus sofosbuvir with/without ribavirin in HCV genotype 1 prior null-responder/treatment-naive patients (Cosmos study): primary endpoint (SVR12) results in patients with metavir F3-4 (Cohort 2). Journal of Hepatology 2014; 60: S524-S524
    PubMedGoogle Scholar
  • 54 Sulkowski M, Jacobson IM, Ghalib R et al. Once-daily simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 prior null responders with metavir F0-2: Cosmos study subgroup analysis. Journal of Hepatology 2014; 60: S4-S4
    PubMedGoogle Scholar
  • 55 Charlton M, Gane E, Manns MP et al. Sofosbuvir and ribavirin for the treatment of established recurrent hepatitis C infeciton after liver transplantation: preliminary results of a prospective, multicenter study. Hepatology 2013; 58: LB-2
    PubMedGoogle Scholar
  • 56 Pellicelli AM, Montalbano M, Lionetti R et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late. Dig Liver Dis 2014; 46: 923-927
    CrossrefPubMedGoogle Scholar
  • 57 Donaldson EF, Harrington PR, O'Rear JJ et al. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology 2015; 61: 56-65
    CrossrefPubMedGoogle Scholar
  • 58 Manns M, Pol S, Jacobson IM et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014; 384: 1597-1605
    CrossrefPubMedGoogle Scholar
  • 59 Krishnan P, Tripathi R, Schnell G et al. Pooled analysis of resistance in patients treated with ombitasvir/ABT-450/r and dasabuvir with or without ribavirin in Phase 2 and Phase 3 clinical trials. Hepatology 2014; 60: 1134a-1135a
    PubMedGoogle Scholar
  • 60 Sarrazin C, Dvory-Sobol H, Svarovskaia ES et al. Baseline and Post-baseline Resistance Analyses of Phase 2/3 Studies of Ledipasvir/Sofosbuvir ± RBV. Hepatology 2014; 60: 1128a-1128a
    CrossrefPubMedGoogle Scholar
  • 61 Lenz O, Verbinnen T, Fevery B et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies. J Hepatol 2014; epub ahead of print
    PubMedGoogle Scholar
  • 62 Sullivan JC, De Meyer S, Bartels DJ et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Journal of Hepatology 2011; 54 (Suppl. 01) S4-S4
    PubMedGoogle Scholar
  • 63 Reddy KR, Pol S, Thuluvath PJ et al. Long-term follow-up of patients treated with daclatasvir-based regimens in phase 2 and 3 studies. Hepatology 2014; 60: 1154a-1155a
    PubMedGoogle Scholar
  • 64 Howe AY, Long JM, Thompson S et al. Analysis of the Durability of Response and Persistance of Resistance Associated Variants during Long Term Follow Up after Boceprevir plus Pegylated Interferon/Ribavirin Therapy-3 Year Analysis. Hepatology 2013; 58: 1095a-1095a
    PubMedGoogle Scholar
  • 65 Svarovskaia ES, Dvory-Sobol H, Parkin N et al. Infrequent Development of Resistance in Genotype 1-6 Hepatitis C Virus-Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials. Clinical Infectious Diseases 2014; 59: 1666-1674
    CrossrefPubMedGoogle Scholar
  • 66 Bourliere M, Bronowicki JP, de Ledinghen V et al. Ledipasvir/Sofosbuvir Fixed Dose Combination is Safe and Efficacious in Cirrhotic Patients Who Have Previously Failed Protease-Inhibitor Based Triple Therapy. Hepatology 2014; 60: 1270a-1271a
    PubMedGoogle Scholar